Investigational procedures in benign prostatic hypertrophy

Joseph Acquaye, Michael S Borofsky

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Purpose of review As benign prostatic hypertrophy (BPH) becomes a more common disease, there has been a dramatic rise in the number of investigational procedures being developed to manage it. We seek to present an overview of the most recently developed treatments and present clinical data related to application wherever available. Recent findings As a greater number of treatments become available for BPH, improved diagnostic testing could prove beneficial in helping guide patient selection. Efforts are underway to identify serum biomarkers associated with BPH as well as new classifications strategies, specifically with MRI, to determine both the anatomy of BPH as well as its histologic distribution. Outpatient-based procedures for BPH currently being developed include the temporary implantable nitinol device as well as intraprostatic injections such as Botox and PRX302. Aquablation is a novel technique that uses robotically guided high-pressured saline to ablate prostate tissue. Early data suggests noninferiority compared with TURP. Finally, efforts are underway to apply robotics to BPH with the advent of a robotic transurethral platform being designed for prostate enucleation. Summary Many new techniques are poised to be introduced to the BPH market over the coming years. The unique risk/benefit profiles as well as associated clinical outcomes of each will need to be studied in detail in order to help identify proper roles in the management of patients with symptomatic disease.

Original languageEnglish (US)
Pages (from-to)315-321
Number of pages7
JournalCurrent Opinion in Urology
Volume28
Issue number3
DOIs
StatePublished - May 1 2018

Fingerprint

Prostatic Hyperplasia
Robotics
Prostate
Transurethral Resection of Prostate
Patient Selection
Anatomy
Outpatients
Biomarkers
Equipment and Supplies
Injections
Therapeutics
Serum

Keywords

  • benign prostatic hypertrophy
  • investigational
  • procedure
  • prostate
  • technology

Cite this

Investigational procedures in benign prostatic hypertrophy. / Acquaye, Joseph; Borofsky, Michael S.

In: Current Opinion in Urology, Vol. 28, No. 3, 01.05.2018, p. 315-321.

Research output: Contribution to journalReview article

@article{1b69385b8f2d4295937228d4eb5c4a2d,
title = "Investigational procedures in benign prostatic hypertrophy",
abstract = "Purpose of review As benign prostatic hypertrophy (BPH) becomes a more common disease, there has been a dramatic rise in the number of investigational procedures being developed to manage it. We seek to present an overview of the most recently developed treatments and present clinical data related to application wherever available. Recent findings As a greater number of treatments become available for BPH, improved diagnostic testing could prove beneficial in helping guide patient selection. Efforts are underway to identify serum biomarkers associated with BPH as well as new classifications strategies, specifically with MRI, to determine both the anatomy of BPH as well as its histologic distribution. Outpatient-based procedures for BPH currently being developed include the temporary implantable nitinol device as well as intraprostatic injections such as Botox and PRX302. Aquablation is a novel technique that uses robotically guided high-pressured saline to ablate prostate tissue. Early data suggests noninferiority compared with TURP. Finally, efforts are underway to apply robotics to BPH with the advent of a robotic transurethral platform being designed for prostate enucleation. Summary Many new techniques are poised to be introduced to the BPH market over the coming years. The unique risk/benefit profiles as well as associated clinical outcomes of each will need to be studied in detail in order to help identify proper roles in the management of patients with symptomatic disease.",
keywords = "benign prostatic hypertrophy, investigational, procedure, prostate, technology",
author = "Joseph Acquaye and Borofsky, {Michael S}",
year = "2018",
month = "5",
day = "1",
doi = "10.1097/MOU.0000000000000494",
language = "English (US)",
volume = "28",
pages = "315--321",
journal = "Current Opinion in Urology",
issn = "0963-0643",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Investigational procedures in benign prostatic hypertrophy

AU - Acquaye, Joseph

AU - Borofsky, Michael S

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Purpose of review As benign prostatic hypertrophy (BPH) becomes a more common disease, there has been a dramatic rise in the number of investigational procedures being developed to manage it. We seek to present an overview of the most recently developed treatments and present clinical data related to application wherever available. Recent findings As a greater number of treatments become available for BPH, improved diagnostic testing could prove beneficial in helping guide patient selection. Efforts are underway to identify serum biomarkers associated with BPH as well as new classifications strategies, specifically with MRI, to determine both the anatomy of BPH as well as its histologic distribution. Outpatient-based procedures for BPH currently being developed include the temporary implantable nitinol device as well as intraprostatic injections such as Botox and PRX302. Aquablation is a novel technique that uses robotically guided high-pressured saline to ablate prostate tissue. Early data suggests noninferiority compared with TURP. Finally, efforts are underway to apply robotics to BPH with the advent of a robotic transurethral platform being designed for prostate enucleation. Summary Many new techniques are poised to be introduced to the BPH market over the coming years. The unique risk/benefit profiles as well as associated clinical outcomes of each will need to be studied in detail in order to help identify proper roles in the management of patients with symptomatic disease.

AB - Purpose of review As benign prostatic hypertrophy (BPH) becomes a more common disease, there has been a dramatic rise in the number of investigational procedures being developed to manage it. We seek to present an overview of the most recently developed treatments and present clinical data related to application wherever available. Recent findings As a greater number of treatments become available for BPH, improved diagnostic testing could prove beneficial in helping guide patient selection. Efforts are underway to identify serum biomarkers associated with BPH as well as new classifications strategies, specifically with MRI, to determine both the anatomy of BPH as well as its histologic distribution. Outpatient-based procedures for BPH currently being developed include the temporary implantable nitinol device as well as intraprostatic injections such as Botox and PRX302. Aquablation is a novel technique that uses robotically guided high-pressured saline to ablate prostate tissue. Early data suggests noninferiority compared with TURP. Finally, efforts are underway to apply robotics to BPH with the advent of a robotic transurethral platform being designed for prostate enucleation. Summary Many new techniques are poised to be introduced to the BPH market over the coming years. The unique risk/benefit profiles as well as associated clinical outcomes of each will need to be studied in detail in order to help identify proper roles in the management of patients with symptomatic disease.

KW - benign prostatic hypertrophy

KW - investigational

KW - procedure

KW - prostate

KW - technology

UR - http://www.scopus.com/inward/record.url?scp=85045195513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045195513&partnerID=8YFLogxK

U2 - 10.1097/MOU.0000000000000494

DO - 10.1097/MOU.0000000000000494

M3 - Review article

VL - 28

SP - 315

EP - 321

JO - Current Opinion in Urology

JF - Current Opinion in Urology

SN - 0963-0643

IS - 3

ER -